Droperidol on Prevention of Cannabis Hyperemesis Syndrome
NCT ID: NCT05244460
Last Updated: 2023-01-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
45 participants
INTERVENTIONAL
2021-12-02
2023-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Haloperidol, Droperidol, Ondansetron in Cannabis Hyperemesis
NCT05065567
Domperidone for Chronic Nausea and Vomiting
NCT02757534
Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia
NCT03941288
Postoperative Vomiting in Children: Comparison Tri - Versus bi -Prophylaxis
NCT01739985
The Effects of the Anti Nausea Drugs Droperidol and Ondansetron on the Way the Heart Recovers Between Beats
NCT00624208
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention
Patients who receive droperidol 2.5mg intravenous once and diphenhydramine 25mg intravenous once
Droperidol Injectable Product
Treatment
Diphenhydramine
Treatment
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Droperidol Injectable Product
Treatment
Diphenhydramine
Treatment
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Corrected QT interval on ECG greater than 440 milliseconds for males and greater than 450 milliseconds for females
* any prisoners
* pregnant females.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Lake Erie College of Osteopathic Medicine
OTHER
Mercy Health Ohio
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Todd Bolotin, MD
Role: PRINCIPAL_INVESTIGATOR
Mercy Health
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mercy Health - Austintown
Austintown, Ohio, United States
St Elizabeth Boardman Hospital
Boardman, Ohio, United States
St. Joseph-Warren Hospital
Warren, Ohio, United States
St Elizabeth Youngstown Hospital
Youngstown, Ohio, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Ruberto AJ, Sivilotti MLA, Forrester S, Hall AK, Crawford FM, Day AG. Intravenous Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized, Controlled Trial. Ann Emerg Med. 2021 Jun;77(6):613-619. doi: 10.1016/j.annemergmed.2020.08.021. Epub 2020 Nov 5.
Lee C, Greene SL, Wong A. The utility of droperidol in the treatment of cannabinoid hyperemesis syndrome. Clin Toxicol (Phila). 2019 Sep;57(9):773-777. doi: 10.1080/15563650.2018.1564324. Epub 2019 Feb 7.
Hickey JL, Witsil JC, Mycyk MB. Haloperidol for treatment of cannabinoid hyperemesis syndrome. Am J Emerg Med. 2013 Jun;31(6):1003.e5-6. doi: 10.1016/j.ajem.2013.02.021. Epub 2013 Apr 10.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
21-029
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.